Characterization of Endogenous G-CSF and the Inverse Correlation to Chemotherapy-Induced Neutropenia in Patients with Breast Cancer Using Population Modeling

PurposeNeutropenia is a severe adverse-event of chemotherapeutics. Neutrophils (ANC) are mainly regulated by granulocyte colony stimulating factor (G-CSF). The aim was to characterize the dynamics between endogenous G-CSF and ANC over time following chemotherapy.MethodsEndogenous G-CSF and ANC were monitored in forty-nine breast cancer patients treated with sequential adjuvant 5-fluorouracil–epirubicin–cyclophosphamide and docetaxel.ResultsDuring treatment courses ANC was transiently decreased and was reflected in an endogenous G-CSF increase, which was well described by a semi-mechanistic model including control mechanisms; when G-CSF concentrations increased the proliferation rate increased and the bone maturation time reduced for ANC. Subsequently, ANC in the circulation increased leading to increased elimination of G-CSF. Additionally, a non-specific elimination for G-CSF was quantified. The ANC-dependent elimination contributed to 97% at baseline and 49% at an ANC of 0.1 · 109/L to the total G-CSF elimination.ConclusionThe integrated G-CSF–myelosuppression model captured the initial rise in endogenous G-CSF following chemotherapy-induced neutropenia and the return to baseline of G-CSF and ANC. The model supported the self-regulatory properties of the system and may be a useful tool for further characterization of the biological system and in optimization of chemotherapy treatment.

[1]  W. Evans,et al.  Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. , 1992 .

[2]  T. Whitsett,et al.  Effects of a single, large, intravenous iniection of dexamethasone , 1972, Clinical pharmacology and therapeutics.

[3]  J. Bergh,et al.  Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients , 2006, Cancer Chemotherapy and Pharmacology.

[4]  R. Ramakrishnan,et al.  Basic Pharmacodynamic Models for Agents That Alter Production of Natural Cells , 1999, Journal of Pharmacokinetics and Biopharmaceutics.

[5]  Mats O Karlsson,et al.  Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Lewis B. Sheiner,et al.  A population pharmacokinetic model for docetaxel (Taxotere®): Model building and validation , 1996, Journal of Pharmacokinetics and Biopharmaceutics.

[7]  M. Fukuda,et al.  Levels of recombinant human granulocyte colony-stimulating factor in serum are inversely correlated with circulating neutrophil counts , 1996, Antimicrobial agents and chemotherapy.

[8]  Gisela Schwab,et al.  Pharmacokinetic/Pharmacodynamic Modeling of Pegfilgrastim in Healthy Subjects , 2006, Journal of clinical pharmacology.

[9]  Y. Sawada,et al.  Pharmacokinetic/pharmacodynamic analysis of neutrophil proliferation induced by recombinant granulocyte colony-stimulating factor (rhG-CSF): comparison between intravenous and subcutaneous administration. , 1997, Biological & pharmaceutical bulletin.

[10]  Bing Wang,et al.  Population Pharmacokinetic–Pharmacodynamic Modeling of Filgrastim (r-metHuG-CSF) in Healthy Volunteers , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[11]  W. Jusko,et al.  Dose Equivalency Evaluation of Major Corticosteroids: Pharmacokinetics and Cell Trafficking and Cortisol Dynamics , 2003, Journal of clinical pharmacology.

[12]  Y. Sugiyama,et al.  Kinetic analysis of receptor-mediated endocytosis of G-CSF derivative, nartograstim, in rat bone marrow cells. , 1996, The American journal of physiology.

[13]  L. Roskos,et al.  Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats. , 2004, Journal of pharmaceutical sciences.

[14]  G. Welzl,et al.  Regulated plasma levels of colony‐stimulating factors, interleukin‐6 and interleukin‐10 in patients with acute leukaemia and non‐Hodgkin's lymphoma undergoing cytoreductive chemotherapy , 1996, British journal of haematology.

[15]  T. Kumakawa,et al.  Levels of serum granulocyte colony-stimulating factor in patients with infections. , 1990, Blood.

[16]  Mats O. Karlsson,et al.  Use of Prior Information to Stabilize a Population Data Analysis , 2002, Journal of Pharmacokinetics and Pharmacodynamics.

[17]  H. Eichler,et al.  Glucocorticoids dose-dependently increase plasma levels of granulocyte colony stimulating factor in man. , 1998, The Journal of clinical endocrinology and metabolism.

[18]  A. Roberts G-CSF: A key regulator of neutrophil production, but that's not all! , 2005, Growth factors.

[19]  Wojciech Krzyzanski,et al.  Population Pharmacokinetic Modelling of Filgrastim in Healthy Adults following Intravenous and Subcutaneous Administrations , 2009, Clinical pharmacokinetics.

[20]  Wojciech Krzyzanski,et al.  Population Modeling of Filgrastim PK‐PD in Healthy Adults Following Intravenous and Subcutaneous Administrations , 2010, Journal of clinical pharmacology.

[21]  M. Piccart,et al.  Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  T. Iga,et al.  Pharmacokinetic/pharmacodynamic analysis of neutrophil proliferation induced by rhG-CSF in patients receiving antineoplastic drugs. , 2004, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[23]  L. Hareng,et al.  Induction and Regulation of Endogenous Granulocyte Colony-Stimulating Factor Formation , 2002, Biological chemistry.

[24]  Mats O Karlsson,et al.  Model-based neutrophil-guided dose adaptation in chemotherapy: evaluation of predicted outcome with different types and amounts of information. , 2010, Basic & clinical pharmacology & toxicology.

[25]  T. Dexter,et al.  The regulation of hemopoietic cell development by the stromal cell environment and diffusible regulatory molecules. , 1984, Progress in clinical and biological research.

[26]  Mats O. Karlsson,et al.  Mechanistic Models for Myelosuppression , 2003, Investigational New Drugs.

[27]  Y. Kato,et al.  Increased serum human granulocyte colony-stimulating factor (G-CSF) levels following intravenous infusion of high-dose methylprednisolone. , 1996, Endocrine journal.

[28]  Ss Beal,et al.  NONMEM User’s Guides. (1989–2009) , 2009 .

[29]  S. Higuchi,et al.  Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Recombinant Human Granulocyte Colony Stimulating Factor (Lenograstim) Administration , 1999, Journal of clinical pharmacology.

[30]  I. Trocóniz,et al.  Comparison of different semi-mechanistic models for chemotherapy-related neutropenia: application to BI 2536 a Plk-1 inhibitor , 2011, Cancer Chemotherapy and Pharmacology.

[31]  Mats O. Karlsson,et al.  Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression , 2010, Cancer Chemotherapy and Pharmacology.

[32]  L B Sheiner,et al.  A population model for the leukopenic effect of etoposide , 1995, Clinical pharmacology and therapeutics.

[33]  D. Concordet,et al.  Model-Based Approach to Describe G-CSF Effects in Carboplatin-Treated Cancer Patients , 2013, Pharmaceutical Research.

[34]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .

[35]  A. Goldhirsch,et al.  Dose–response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer , 1998 .

[36]  T. Dexter Regulation of hemopoietic cell growth and development: experimental and clinical studies. , 1989, Leukemia.

[37]  I. Trocóniz,et al.  Prediction of Neutropenia‐Related Effects of a New Combination Therapy With the Anticancer Drugs BI 2536 (a Plk1 Inhibitor) and Pemetrexed , 2010, Clinical pharmacology and therapeutics.

[38]  Y. Sugiyama,et al.  Pharmacokinetics and pharmacodynamics of a recombinant human granulocyte colony-stimulating factor. , 1996, Drug metabolism reviews.

[39]  S. Urien,et al.  Pharmacokinetic Modelling of 5-FU Production from Capecitabine—A Population Study in 40 Adult Patients with Metastatic Cancer , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[40]  Hitoshi Sato,et al.  Population pharmacokinetic and pharmacodynamic analysis for time courses of docetaxel‐induced neutropenia in Japanese cancer patients , 2007, Cancer science.

[41]  M. Karlsson,et al.  Models of schedule dependent haematological toxicity of 2'-deoxy-2'-methylidenecytidine (DMDC) , 2000, European Journal of Clinical Pharmacology.

[42]  M. Marty,et al.  Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. , 1993, Cancer research.

[43]  G. Lyman,et al.  Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. , 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

[44]  M. Karlsson,et al.  A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model , 2012, Investigational New Drugs.

[45]  J. Friedberg,et al.  Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  G. Weiss,et al.  Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.